Cancer Database Query Results

HCC, Hepatocellular Carcinoma: Click to Expand ⟱
Hepatocellular Carcinoma
Scientific Papers found: Click to Expand⟱
2424- 2DG,  SRF,    The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells
- in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
ChemoSen↓, Glycolysis↓, HK1↓, HK2↓, ATP↓,
2423- 2DG,  SRF,    2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells
- in-vitro, HCC, NA
ChemoSen↑, TumCP↓, cycD1/CCND1↓, MMP9↓,
5276- 3BP,    A Translational Study 'Case Report' on the Small Molecule 'Energy Blocker' 3-Bromopyruvate (3BP) as a Potent Anticancer Agent: From Bench Side to Bedside(2012)
- Case Report, HCC, NA
Dose↓, Remission↑,
5259- 3BP,    Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP
- in-vivo, HCC, NA
ATP↓, TumCD↑, toxicity↓, eff↑, tumCV↓, Dose↝,
5269- 3BP,    The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models.
- in-vitro, HCC, NA
toxicity↑, eff↝, eff↑, Glycolysis↓, HK2↓, AIF↑, Apoptosis↑, NK cell↑, toxicity↑, toxicity↓, Dose↝, AntiTum↑,
1027- AG,    Astragalus polysaccharide (APS) attenuated PD-L1-mediated immunosuppression via the miR-133a-3p/MSN axis in HCC
- vitro+vivo, HCC, SMMC-7721 cell
PD-L1↓, miR-133a-3p↝,
5436- AG,    Therapeutic Effect of Astragalus Polysaccharides on Hepatocellular Carcinoma H22-Bearing Mice
- in-vivo, HCC, NA
TumCG↓, BAX↑, Bcl-2↓, IL2↑, IL6↑, TNF-α↑, toxicity↓,
5238- AgNPs,    β-Sitosterol-assisted silver nanoparticles activates Nrf2 and triggers mitochondrial apoptosis via oxidative stress in human hepatocellular cancer cell line
- in-vitro, HCC, HepG2
TumCP↓, ROS↑, NRF2↑, BAX↑, P53↑, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-2↓,
339- AgNPs,    Cancer cell specific cytotoxic potential of the silver nanoparticles synthesized using the endophytic fungus, Penicillium citrinum CGJ-C2
- in-vitro, BC, MCF-7 - in-vitro, Melanoma, A431 - in-vitro, HCC, HepG2
TumCD↑,
2659- AL,    Allicin inhibits spontaneous and TNF-α induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells
- in-vitro, HCC, HT29 - in-vitro, HCC, Caco-2
IL1β↓, IL8↓, Inflam↓,
234- AL,    Allicin Induces Anti-human Liver Cancer Cells through the p53 Gene Modulating Apoptosis and Autophagy
- in-vitro, HCC, Hep3B
ROS↑, *toxicity∅, MMP↓, BAX↑, Bcl-2↓, AIF↑, Casp3↑, Casp8↑, Casp9↑, eff↓, γH2AX↑, selectivity↑, DNA-PK↑,
264- ALA,    α-Lipoic acid induces Endoplasmic Reticulum stress-mediated apoptosis in hepatoma cells
- in-vitro, HCC, FaO
ROS↑, P53↑, ER Stress↑, UPR↑, CHOP↑, PDI↑, GRP78/BiP↑, GRP58↓,
276- ALA,    Alpha lipoic acid diminishes migration and invasion in hepatocellular carcinoma cells through an AMPK-p53 axis
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B
P53↑, EMT↓, AMPK↑, cycD1/CCND1↓, TumCMig↓,
2586- Api,  doxoR,    Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway
- in-vitro, HCC, Bel-7402
NRF2↓, ChemoSen↑,
586- Api,  5-FU,    5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma
- in-vivo, HCC, NA
ROS↑, MMP↓, Bcl-2↓, Casp3↑, PARP↑,
938- Api,  doxoR,    Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells
- vitro+vivo, HCC, HepG2
LDHA↓, HK2↓,
3174- Ash,    Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
NF-kB↓, angioG↓, Inflam↓, TumCP↓, TumCMig↓, TumCI↓, Sp1/3/4↓, VEGF↓, angioG↓, uPA↓, PDGF↓, MCP1↓, ICAM-1↓, *NRF2↑, *hepatoP↑,
3172- Ash,    Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis
- in-vitro, HCC, HepG2 - in-vitro, Nor, HL7702
Keap1↑, NRF2↓, EMT↓, TumCP↓, TumCI↓, selectivity↑, *toxicity↓, ROS↑, MDA↑, GSH↓, Ferroptosis↑,
5363- AV,    Exploring the mechanism of aloe-emodin in the treatment of liver cancer through network pharmacology and cell experiments
- Study, HCC, NA
AKT1↓, EGFR↓, PI3K↓, Bcl-2↓, TumCG↓, Apoptosis↑,
1029- Ba,  BA,    Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells
- vitro+vivo, HCC, NA
PD-L1↓, T-Cell↑, STAT3↓,
2479- Ba,    Baicalein Overcomes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells
- in-vitro, HCC, SW480 - in-vitro, Pca, PC3
12LOX↓, DR5↑, CHOP↑, ROS↑, *ROS∅, selectivity↑,
2608- Ba,    Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity
- in-vitro, HCC, Bel-7402
Apoptosis↑, TumAuto↑, P-gp↓, Bcl-xL↓, ChemoSen↑,
2606- Ba,    Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma
- Review, HCC, NA
ChemoSen↑, TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, MMPs↓, MAPK↓, TGF-β↓, ZFX↓, p‑MEK↓, ERK↓, MMP2↓, MMP9↓, uPA↓, TIMP1↓, TIMP2↓, NF-kB↓, p65↓, p‑IKKα↓, Fas↑, Casp2↑, Casp3↑, Casp8↑, Casp9↑, Bcl-xL↓, BAX↑, ER Stress↑, Ca+2↑, JNK↑, P53↑, ROS↑, H2O2↑, cMyc↓, CD24↓, 12LOX↓,
2600- Ba,    Baicalein Induces Apoptosis and Autophagy via Endoplasmic Reticulum Stress in Hepatocellular Carcinoma Cells
- in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, Bel-7402
ER Stress↑, Bcl-2↓, Ca+2↑, JNK↑, CHOP↑, Casp9↑, Casp3↑, PARP↑, Apoptosis↑, UPR↑,
2619- Ba,    Tumor cell membrane-coated continuous electrochemical sensor for GLUT1 inhibitor screening
- in-vitro, HCC, HepG2 - in-vitro, GBM, U87MG - in-vitro, BC, MGC803 - in-vitro, Lung, A549
GLUT1↓, TumCP↓,
5554- BBM,  SRF,    Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells
- in-vitro, HCC, NA
ChemoSen↑, STAT3↓,
2706- BBR,    Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake
- in-vitro, HCC, Hep3B - in-vitro, HCC, Bel-7402 - in-vivo, NA, NA
TumCP↓, glut↓, SLC12A5↓, cMyc↓, GLS↓,
2709- BBR,    Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α
- in-vitro, HCC, HepG2
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, Glycolysis↓, Hif1a↓, GLUT1↓, HK2↓, PKM2↓, LDHA↓,
5548- BBR,    Berbamine induces SMMC-7721 cell apoptosis via upregulating p53, downregulating survivin expression and activating mitochondria signaling pathway
- in-vitro, HCC, SMMC-7721 cell
TumCG↓, Apoptosis↑, Cyt‑c↑, BAX↑, P53↑, Bcl-2↓, survivin↓,
2756- BetA,    Betulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway
- in-vitro, HCC, HUH7 - in-vitro, HCC, H1299
TumCP↓, ROS↑, antiOx↓, TumCG↓, TumCMig↓, NRF2↓, GPx4↓, HO-1↓, NCOA4↑, FTH1↓, Ferritin↑, Ferroptosis↑, GSH↓, MDA↓,
5716- BF,    Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, or Pancreatic Cancer
- Trial, NSCLC, NA - Trial, PC, NA - Trial, HCC, NA
Dose↝, toxicity↓, other↓, QoL↑, OS?,
5481- BM,    Therapeutic potential of Bacopa monnieri extracts against hepatocellular carcinoma through in-vitro and computational studies
- in-vitro, HCC, HepG2
tumCV↓, Apoptosis↑, TumCP↓, TumCMig↓, TumCI↓, MMP2↓, MMP9↓, lipid-P↓,
744- Bor,    Borax affects cellular viability by inducing ER stress in hepatocellular carcinoma cells by targeting SLC12A5
- in-vitro, HCC, HepG2 - in-vitro, Nor, HL7702
TumCCA↑, SLC12A5↓, ATF6↑, CHOP↑, GRP78/BiP↑, Casp3↑, ER Stress↝, *toxicity↓, *eff↓,
725- Bor,    Boric acid exert anti-cancer effect in poorly differentiated hepatocellular carcinoma cells via inhibition of AKT signaling pathway
- in-vitro, HCC, NA
tumCV↓, Apoptosis↑, TumAuto↑, p‑Akt↓,
5693- BRU,    Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2
- in-vivo, HCC, NA
NRF2↓, eff↑, p‑MAPK↑, p‑Akt↑, p‑ERK↑, p‑JNK↑,
5698- BRU,    Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma
- in-vitro, HCC, NA
TumCMig↓, EMT↓, STAT3↓, E-cadherin↑, NRF2↓, ChemoSen↑, RadioS↑, DNAdam↑, TumCMig↓, TumCI↓, toxicity↓,
5752- CA,    Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma
- Review, HCC, NA
*ROS↓, angioG↓, STAT3↓, MMP2?, MMP9?,
5201- CAP,    Inhibiting ROS-STAT3-dependent autophagy enhanced capsaicin-induced apoptosis in human hepatocellular carcinoma cells
- NA, HCC, HepG2
AntiCan↓, Apoptosis↑, cl‑PARP↑, Bcl-2↑, TumAuto↑, LC3II↑, eff↑, STAT3↑, ROS↑, eff↓,
1264- CAP,    Capsaicin modulates proliferation, migration, and activation of hepatic stellate cells
- in-vitro, HCC, NA
TumCP↓, TumCMig↓, TumCCA↑, MMP∅, MMP2↓, MMP9↓, α-SMA↓, COL1A1↓, COL3A1↓, TIMP1↓,
2018- CAP,  MF,    Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma
- Review, HCC, NA
TRPV1↑, eff↑, Akt↓, mTOR↓, p‑STAT3↑, MMP2↑, ER Stress↑, Ca+2↑, ROS↑, selectivity↑, MMP↓, eff↑,
5773- CAPE,    Caffeic acid phenethyl ester inhibits invasion and expression of matrix metalloproteinase in SK-Hep1 human hepatocellular carcinoma cells by targeting nuclear factor kappa B
- NA, HCC, SK-HEP-1
TumCI↓, MMP2↓, MMP9↓, NF-kB↓, TumMeta↓,
5763- CAPE,    Synthesis and Biological Evaluation of a Caffeic Acid Phenethyl Ester Derivatives as Anti-Hepatocellular Carcinoma Agents via Inhibition of Mitochondrial Respiration and Disruption of Cellular Metabolism
- NA, HCC, NA
*antiOx↑, *neuroP↑, NF-kB↓, TumCG↓, TumMeta↓, MMPs↓, P53↑, ChemoSen↑,
4479- Chit,    Chitosan nanoparticles triggered the induction of ROS-mediated cytoprotective autophagy in cancer cells
- in-vitro, Cerv, HeLa - in-vitro, HCC, SMMC-7721 cell
TumAuto↑, ROS↑, eff↓,
1144- CHr,    8-bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK
- in-vitro, HCC, HepG2 - in-vitro, HCC, Bel-7402 - in-vitro, Nor, HL7702
Casp3↑, *ROS∅, ROS↑, JNK↑, *toxicity↓,
1033- CHr,    Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression
- vitro+vivo, HCC, NA
TumCG↓, CD4+↑, CD8+↑, PD-L1↓,
1143- CHr,    Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2
- in-vitro, HCC, HepG2 - in-vivo, NA, NA - in-vitro, HCC, HepG3 - in-vitro, HCC, HUH7
HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, Apoptosis↑,
2591- CHr,  doxoR,    Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway
- in-vitro, HCC, Bel-7402
NRF2↓, ChemoSen↑, HO-1↓,
2820- CUR,    Hepatoprotective Effect of Curcumin on Hepatocellular Carcinoma Through Autophagic and Apoptic Pathways
- in-vitro, HCC, HepG2
*hepatoP↑, *ROS↓, tumCV↓,
5008- DSF,  Cu,    Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis
- in-vitro, HCC, NA
selectivity↑, TumCD↑, TumCMig↓, TumCI↓, angioG↓, mtDam↑, Iron↑, lipid-P↑, Ferroptosis↑, NF-kB↑, p‑p62↑, Keap1↓, eff↑, eff↓, ChemoSen↑,
989- EGCG,  Citrate,    In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity
- in-vitro, HCC, NA - in-vivo, NA, NA
PFK↓, Glycolysis↓, lactateProd↓, GlucoseCon↓, TumCP↓, TumCCA↑, Casp3↑, cl‑PARP↑, Apoptosis↑, Casp8↑, Casp9↑, Cyt‑c↝, MMP↓, BAD↑, GLUT2↓, PKM2∅,

Showing Research Papers: 1 to 50 of 102
Page 1 of 3 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 102

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   Ferroptosis↑, 3,   GPx4↓, 1,   GSH↓, 2,   H2O2↑, 1,   HK1↓, 1,   HO-1↓, 2,   Iron↑, 1,   Keap1↓, 1,   Keap1↑, 1,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↓, 1,   MDA↑, 1,   NRF2↓, 6,   NRF2↑, 1,   ROS↑, 12,  

Metal & Cofactor Biology ⓘ

Ferritin↑, 1,   FTH1↓, 1,   NCOA4↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 2,   ATP↓, 2,   p‑MEK↓, 1,   MMP↓, 4,   MMP∅, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 2,   AKT1↓, 1,   AMPK↑, 1,   cMyc↓, 2,   GLS↓, 1,   GlucoseCon↓, 2,   glut↓, 1,   GLUT2↓, 1,   Glycolysis↓, 5,   HK2↓, 5,   lactateProd↓, 2,   LDHA↓, 2,   PFK↓, 1,   PKM2↓, 1,   PKM2∅, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   p‑Akt↑, 1,   Apoptosis↑, 11,   BAD↑, 1,   BAX↑, 5,   Bcl-2↓, 7,   Bcl-2↑, 1,   Bcl-xL↓, 2,   Casp2↑, 1,   Casp3↑, 8,   Casp8↑, 3,   Casp9↑, 5,   Cyt‑c↑, 2,   Cyt‑c↝, 1,   DR5↑, 1,   Fas↑, 1,   Ferroptosis↑, 3,   GRP58↓, 1,   JNK↑, 3,   p‑JNK↑, 1,   MAPK↓, 1,   p‑MAPK↑, 1,   survivin↓, 1,   TRPV1↑, 1,   TumCD↑, 3,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

ATF6↑, 1,   CHOP↑, 4,   ER Stress↑, 4,   ER Stress↝, 1,   GRP78/BiP↑, 2,   UPR↑, 2,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   p‑p62↑, 1,   TumAuto↑, 4,  

DNA Damage & Repair ⓘ

DNA-PK↑, 1,   DNAdam↑, 1,   P53↑, 6,   PARP↑, 2,   cl‑PARP↑, 2,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 2,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

CD24↓, 1,   EMT↓, 3,   ERK↓, 1,   p‑ERK↑, 1,   mTOR↓, 1,   PI3K↓, 1,   STAT3↓, 4,   STAT3↑, 1,   p‑STAT3↑, 1,   TumCG↓, 6,   ZFX↓, 1,  

Migration ⓘ

Ca+2↑, 3,   COL1A1↓, 1,   COL3A1↓, 1,   E-cadherin↑, 1,   miR-133a-3p↝, 1,   MMP2?, 1,   MMP2↓, 4,   MMP2↑, 1,   MMP9?, 1,   MMP9↓, 5,   MMPs↓, 2,   PDGF↓, 1,   TGF-β↓, 1,   TIMP1↓, 2,   TIMP2↓, 1,   TumCI↓, 8,   TumCMig↓, 10,   TumCP↓, 12,   TumMeta↓, 2,   uPA↓, 2,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   EGFR↓, 1,   Hif1a↓, 1,   PDI↑, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 2,   P-gp↓, 1,   SLC12A5↓, 2,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   ICAM-1↓, 1,   p‑IKKα↓, 1,   IL1β↓, 1,   IL2↑, 1,   IL6↑, 1,   IL8↓, 1,   Inflam↓, 2,   MCP1↓, 1,   NF-kB↓, 4,   NF-kB↑, 1,   NK cell↑, 1,   p65↓, 1,   PD-L1↓, 3,   T-Cell↑, 1,   TNF-α↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↓, 1,   ChemoSen↑, 9,   Dose↓, 1,   Dose↝, 3,   eff↓, 4,   eff↑, 7,   eff↝, 1,   RadioS↑, 1,   selectivity↑, 5,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   Ferritin↑, 1,   IL6↑, 1,   PD-L1↓, 3,  

Functional Outcomes ⓘ

AntiCan↓, 1,   AntiTum↑, 1,   OS?, 1,   QoL↑, 1,   Remission↑, 1,   toxicity↓, 5,   toxicity↑, 2,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 164

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   NRF2↑, 1,   ROS↓, 2,   ROS∅, 2,  

Drug Metabolism & Resistance ⓘ

eff↓, 1,  

Functional Outcomes ⓘ

hepatoP↑, 2,   neuroP↑, 1,   toxicity↓, 3,   toxicity∅, 1,  
Total Targets: 9

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:10  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page